October 24th, 2024 “EURETINA-Brief”© Issue No. 302
Dear EURETINA Members, A very warm welcome to the October 24th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue…
EURETINA’s
DIGITAL
NEWSLETTER
Featured Articles
1
October 24th, 2024
Latest News
October 24th, 2024 “EURETINA-Brief”© Issue No. 302
Dear EURETINA Members, A very warm welcome to the October 24th, 2024 edition of EURETINA’s…
A new research study on RPE curvature may provides a promising quantitative biomarker for late AMD.
Researchers at the University of New South Wales, Sydney, Australia, have reported a new study…
Endpoints and clinical trial design for IRDs and USH2A reporting outcomes from a natural history study.
An international clinical research consortium has reported recommendations on endpoints and design of clinical trials…
Ocuphire Pharma Inc., has acquired Opus Genetics, aimed to advance treatments quickly for several ophthalmic indications.
Ocuphire Pharma, Inc. (Nasdaq: OCUP), based in Farmington Hills, Michigan, USA announced the all-stock acquisition…